The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host

Cancer and Metastasis Reviews

Volumn 27, Issue 3, 2008, Pages 523-537

  Podhajcer, Osvaldo L ^a,b   Benedetti, Lorena ^a   Girotti, Maria Romina ^a   Prada, Federico ^a   Salvatierra, Edgardo ^a   Llera, Andrea S ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Angiogenesis; Cancer; EMT; Extracellular matrix; SPARC

Indexed keywords

MATRIX PROTEIN; OSTEONECTIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTITUMOR GENE; BREAST CANCER; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER THERAPY; CARCINOGENIC ACTIVITY; CARCINOMA; CELL INTERACTION; CELL TRANSFORMATION; DNA MICROARRAY; EPITHELIUM CELL; EXTRACELLULAR MATRIX; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSURVEILLANCE; MESENCHYME CELL; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TUMOR VASCULARIZATION;

ANIMALS; CELL COMMUNICATION; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; OSTEONECTIN; RECEPTOR CROSS-TALK;

EID: 47949132157     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9135-x     Document Type: Review

References (195)

1. Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100, 57-70.
2. Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour-host interface. Nature, 411, 375-379.
3. Murphy-Ullrich, J. E. (2001). The de-adhesion activity of matricellular proteins: Is intermediate cell adhesion an adaptive state. Journal of Clinical Investigation, 107(7), 785-790.
4. Bornstein, P. (2002). Cell-matrix interactions: The view from the outside. Methods in Cell Biology, 69, 7-11.
5. Sage, E. H. (2001). Regulation of interactions between cells and extracellular matrix: A command performance on several stages. Journal of Clinical Investigation, 107(7), 781-783.
6. Rosenblatt, S., Bassuk, J. A., Alpers, C. E., Sage, E. H., Timpl, R., & Preissner, K. T. (1997). Differential modulation of cell adhesion by interaction between adhesive and counter-adhesive proteins: Characterization of the binding of vitronectin to osteonectin (BM40, SPARC). Biochemical Journal, 324, 311-319.
7. Xie, R. L., & Long, G. L. (1995). Role of N-linked glycosylation in human osteonectin. Effect of carbohydrate removal by N-glycanase and site-directed mutagenesis on structure and binding of type V collagen. Journal of Biological Chemistry, 270(39), 23212-23217.
8. Maurer, P., Hohenadl, C., Hohenester, E., Gohring, W., Timpl, R., & Engel, J. (1995). The C-terminal portion of BM-40 (SPARC/osteonectin) is an autonomously folding and crystallisable domains that binds calcium and collagen IV. Journal of Molecular Biology, 253(2), 347-357.
9. Raines, E. W., Lane, T. F., Iruela-Arispe, M. L., Ross, R., & Sage, E. H. (1992). The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and BB and inhibits the binding of PDGF to its receptors. Proceedings of the National Academy of the Sciences United States of America, 89, 1281-1285.
10. Hasselaar, P., & Sage, E. H. (1992). SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. Journal of Cellular Biochemistry, 49, 272-283.
11. Tremble, P. M., Lane, T. F., Sage, E. H., & Werb, Z. (1993). SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. Journal of Cell Biology, 121(6), 1433-1444.
12. Ledda, M. F., Adris, S., Bravo, A. I., Kairiyama, C., Bover, L., Chernajovsky, Y., et al. (1997). Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nature Medicine, 3(2), 171-175.
13. Lane, T. F., Iruela-Arispe, M. L., & Sage, E. H. (1992). Regulation of gene expression by SPARC during angiogenesis in vitro, changes in fibronectin, thrombospondin-1 and plasminogen activator inhibitor-1. Journal of Biological Chemistry, 267(23), 16736-16745.
14. Gilles, C., Bassuk, J. A., Pulyaeva, H., Sage, E. H., Foidart, J.-M., & Thompson, E. W. (1998). SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Research, 58(23), 5529-5536.
15. 2+ binding EF-hand. Journal of Cellular Biochemistry, 57, 341-350.
16. Brekken, R. A., & Sage, E. H. (2000). SPARC, a matricellular protein: At the crossroads of cell-matrix. Matrix Biology, 19(7), 569-580.
17. Bradshaw, A. D., Francki, A., Motamed, K., Howe, C., & Sage, E. H. (1999). Primary mesenchymal cells isolated from SPARC-null mice exhibit altered morphology and rates of proliferation. Molecular Biology of the Cell, 10(5), 1569-1579.
18. Ledda, M. F., Bravo, A. I., Adris, S., Bover, L., Mordoh, J., & Podhajcer, O. L. (1997). The expression on the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. Journal of Investigative Dermatology, 108(2), 210-214.
19. Rumpler, G., Becker, B., Hafner, C., McClelland, M., Stolz, W., Landthaler, M., et al. (2003). Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Experimental Dermatology, 12(6), 761-771.
20. Massi, D., Franchi, A., Borgognoni, L., Reali, U. M., & Santucci, M. (1999). Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Human Pathology, 30(3), 339-344.
21. Ikuta, Y., Nakatsura, T., Kageshita, T., Fukushima, S., Ito, S., Wakamatsu, K., et al. (2005). Highly sensitive detection of melanoma at an early stage based on the increased serum secreted protein acidic and rich in cysteine and glypican-3 levels. Clinical Cancer Research, 11(22), 8079-8088.
22. Sosa, M. S., Girotti, M. R., Salvatierra, E., Prada, F., de Olmo, J. A., Gallango, S. J., et al. (2007). Proteomic analysis identified N-cadherin, clusterin, and HSP27 as mediators of SPARC (secreted protein, acidic and rich in cysteines) activity in melanoma cells. Proteomics, 7(22), 4123-4134.
23. Smit, D. J., Gardiner, B. B., & Sturm, R. A. (2007). Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. International Journal of Cancer, 121(12), 2653-2660.
24. Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., & Gown, A. M. (1995). Distribution of SPARC in normal and neoplastic human tissue. Journal of Histochemistry and Cytochemistry, 43(8), 791-800.
25. Bellahcene, A., & Castronovo, V. (1995). Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. American Journal of Pathology, 146(1), 95-100.
26. Podhajcer, O. L., Wolf, C., Lefebvre, O., Segain, J. P., Rouyer, N., Stoll, I., et al. (1996). Comparative expression of the SPARC and stromelysin-3 genes in mammary tumors. The Breast, 5, 13-20.
27. Jones, C., Mackay, A., Grigoriadis, A., Cossu, A., Reis-Filho, J. S., Fulford, L., et al. (2004). Expression profiling of purified normal human luminal and myoepithelial breast cells: Identification of novel prognostic markers for breast cancer. Cancer Research, 64(9), 3037-3045.
28. Lien, H. C., Hsiao, Y. H., Lin, Y. S., Yao, Y. T., Juan, H. F., Kuo, W. H., et al. (2007). Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: Identification of genes potentially related to epithelial-mesenchymal transition. Oncogene, 26(57), 7859-7871.
29. Barth, P. J., Moll, R., & Ramaswamy, A. (2005). Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Archiv, 446(5), 532-536.
30. Parker, B. S., Argani, P., Cook, B. P., Liangfeng, H., Chartrand, S. D., Zhang, M., et al. (2004). Alterations in vascular gene expression in invasive breast carcinoma. Cancer Research, 64(21), 7857-7866.
31. Iacobuzio-Donahue, C. A., Argani, P., Hempen, P. M., Jones, J., & Kern, S. E. (2002). The desmoplastic response to infiltrating breast carcinoma: Gene expression at the site of primary invasion and implications for comparisons between tumor types. Cancer Research, 62(18), 5351-5357.
32. Graham, J. D., Balleine, R. L., Milliken, J. S., Bilous, A. M., & Clarke, C. L. (1997). Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. European Journal of Cancer, 33(10), 1654-1660.
33. Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., et al. (2005). Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clinical Cancer Research, 11(14), 5175-5180.
34. Watkins, G., Douglas-Jones, A., Bryce, R., Mansel, R. E., & Jiang, W. G. (2005). Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukotrienes and Essential Fatty Acids, 72(4), 267-272.
35. Rempel, S. A., Golembieski, W. A., Ge, S., Lemke, N., Elisevich, K., Mikkelsen, T., et al. (1998). SPARC: A signal of astrocytic neoplastic transformation and reactive response in human primary and xenograft gliomas. Journal of Neuropathology and Experimental Neurology, 57(12), 1112-1121.
36. Golembieski, W. A., Ge, S., Nelson, K., Mikkelsen, T., & Rempel, S. A. (1999). Increased SPARC expression promotes U87 glioblastoma invasion in vitro. International Journal of Developmental Neuroscience, 17(5-6), 463-472.
37. Rich, J. N., Shi, Q., Hjelmeland, M., Cummings, T. J., Kuan, C. T., Bigner, D. D., et al. (2003). Bone-related genes expressed in advanced malignancies induce invasion and metastasis in a genetically defined human cancer model. Journal of Biological Chemistry, 278(18), 15951-15957.
38. Schultz, C., Lemke, N., Ge, S., Golembieski, W. A., & Rempel, S. A. (2002). Secreted protein acidic and rich in cysteine promotes glioma invasion and delays tumor growth in vivo. Cancer Research, 62, 6270-6277.
39. Vajkoczy, P., Manger, M. D., Goldbrunner, R., Ge, S., Fong, T. A., Vollmar, B., et al. (2000). Targeting angiogenesis inhibits tumor infiltration and expression of the pro-invasive protein SPARC. International Journal of Cancer, 87(2), 261-268.
40. Shi, Q., Bao, S., Maxwell, J. A., Reese, E. D., Friedman, H. S., Bigner, D. D., et al. (2004). Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. Journal of Biological Chemistry, 279(50), 52200-52209.
41. McClung, H. M., Thomas, S. L., Osenkowski, P., Toth, M., Menon, P., Raz, A., et al. (2007). SPARC upregulates MT1-MMP expression, MMP-2 activation, and the secretion and cleavage of galectin-3 in U87MG glioma cells. Neuroscience Letters, 419(2), 172-177.
42. Minn, A. J., Gupta, G. P., Siegel, P. M., Bos, P. D., Shu, W., Giri, D. D., et al. (2005). Genes that mediate breast cancer metastasis to lung. Nature, 436(7050), 518-524.
43. Campo-McKnight, D. A., Sosnoski, D. M., Koblinski, J. E., & Gay, C. V. (2006). Roles of osteonectin in the migration of breast cancer cells into bone. Journal of Cellular Biochemistry, 97(2), 288-302.
44. Jacob, K., Webber, M., Benayahu, D., & Kleinman, H. K. (1999). Osteonectin promotes prostate cancer cell migration and invasion: Possible mechanism for metastasis to bone. Cancer Research, 59(17), 4453-4457.
45. De, S., Chen, J., Narizhneva, N. V., Heston, W., Brainard, J., Sage, E. H., et al. (2003). Molecular pathway for cancer metastasis to bone. Journal of Biological Chemistry, 278(40), 39044-39050.
46. Chen, N., Ye, X. C., Chu, K., Navone, N. M., Sage, E. H., Yu-Lee, L. Y., et al. (2007). A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Research, 67(14), 6544-6548.
47. Koblinski, J. E., Kaplan-Singer, B. R., VanOsdol, S. J., Wu, M., Engbring, J. A., Wang, S., et al. (2005). Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Research, 65(16), 7370-7377.
48. Finocchiaro, G., Mancuso, F. M., Cittaro, D., & Muller, H. (2007). Graph-based identification of cancer signaling pathways from published gene expression signatures using PubLiME. Nucleic Acids Research, 35(7), 2343-2355.
49. Chlenski, A., Liu, S., Crawford, S. E., Volpert, O. V., DeVries, G. H., Evangelista, A., et al. (2002). SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Research, 62(24), 7357-7363.
50. Chlenski, A., Liu, S., Baker, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2004). Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC. Cancer Research, 64(20), 7420-7425.
51. Said, N., Socha, M. J., Olearczyk, J. J., Elmarakby, A. A., Imig, J. D., & Motamed, K. (2007). Normalization of the ovarian cancer microenvironment by SPARC. Molecular Cancer Research, 5(10), 1015-1030.
52. Said, N. A., Najwer, I., Socha, M. J., Fulton, D. J., Mok, S. C., & Motamed, K. (2007). SPARC inhibits LPA-mediated mesothelial-ovarian cancer cell crosstalk. Neoplasia, 9(1), 23-35.
53. Yiu, G. K., Chan, W. Y., Ng, S. W., Chan, P. S., Cheung, K. K., Berkowitz, R. S., et al. (2001). SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. American Journal of Pathology, 159(2), 609-622.
54. Mok, S. C., Chan, W. Y., Wong, K. K., Muto, M. G., & Berkowitz, R. S. (1996). SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells. Oncogene, 12, 1895-1901.
55. Said, N., & Motamed, K. (2005). Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. American Journal of Pathology, 167(6), 1739-1752.
56. Brown, T. J., Shaw, P. A., Karp, X., Huynh, M. H., Begley, H., & Ringuette, M. J. (1999). Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecologic Oncology, 75(1), 25-33.
57. Tai, I. T., Dai, M., Owen, D. A., & Chen, L. B. (2005). Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. Journal of Clinical Investigation, 115(6), 1492-1502.
58. Taghizadeh, F., Tang, M. J., & Tai, I. T. (2007). Synergism between vitamin D and secreted protein acidic and rich in cysteine-induced apoptosis and growth inhibition results in increased susceptibility of therapy-resistant colorectal cancer cells to chemotherapy. Molecular Cancer Therapeutics, 6(1), 309-317.
59. Tang, M. J., & Tai, I. T. (2007). A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. Journal of Biological Chemistry, 282(47), 34457-34467.
60. Yang, E., Kang, H. J., Koh, K. H., Rhee, H., Kim, N. K., & Kim, H. (2007). Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. International Journal of Cancer, 121(3), 567-575.
61. Wiese, A. H., Auer, J., Lassmann, S., Nahrig, J., Rosenberg, R., Hofler, H., et al. (2007). Identification of gene signatures for invasive colorectal tumor cells. Cancer Detection and Prevention, 31(4), 282-295.
62. Nguyen, Q. D., De Wever, O., Bruyneel, E., Hendrix, A., Xie, W. Z., Lombet, A., et al. (2005). Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene, 24(56), 8240-8251.
63. Porte, H., Chastre, E., Prevot, S., Nordlinger, B., Empereur, S., Basset, P., et al. (1995). Neoplastic progression of human colorectal cancer is associated with overexpression of the stromelysin-3 and BM-40/SPARC genes. International Journal of Cancer, 64, 70-75.
64. Guweidhi, A., Kleeff, J., Adwan, H., Giese, N. A., Wente, M. N., Giese, T., et al. (2005). Osteonectin influences growth and invasion of pancreatic cancer cells. Annals of Surgery, 242(2), 224-234.
65. Infante, J. R., Matsubayashi, H., Sato, N., Tonascia, J., Klein, A. P., Riall, T. A., et al. (2007). Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology, 25(3), 319-325.
66. Koukourakis, M. I., Giatromanolaki, A., Brekken, R. A., Sivridis, E., Gatter, K. C., Harris, A. L., et al. (2003). Enhanced expression of SPARC/Osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Research, 63(17), 5376-5380.
67. Sato, N., Fukushima, N., Maehara, N., Matsubayashi, H., Koopmann, J., Su, G. H., et al. (2003). SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene, 22(32), 5021-5030.
68. López Haber, C., Gottifredi, V., Llera, A. S., Salvatierra, E., Prada, F., Alonso, L., et al. (2007). SPARC modulates the proliferation of stromal but not melanoma cells unless endogenous SPARC expression is downregulated. International Journal of Cancer, 122, 1465-1475.
69. Prada, F., Benedetti, L. G., Bravo, A. I., Alvarez, M. J., Carbone, C., & Podhajcer, O. L. (2007). SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. Journal of Investigative Dermatology, 127(11), 2618-2628.
70. Brekken, R. A., Puolakkainen, P., Graves, D. C., Workman, G., Lubkin, S. R., & Sage, E. H. (2003). Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. Journal of Clinical Investation, 111(4), 487-495.
71. Sangaletti, S., Stoppacciaro, A., Guiducci, C., Torrisi, M. R., & Colombo, M. P. (2003). Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. Journal of Experimental Medicine, 198(10), 1475-1485.
72. Framson, P. E., & Sage, E. H. (2004). SPARC and tumor growth: Where the seed meets the soil? Journal of Cellular Biochemistry, 92(4), 679-690.
73. Gooden, M. D., Vernon, R. B., Bassuk, J. A., & Sage, E. H. (1999). Cell cycle-dependent nuclear location of the matricellular protein SPARC: Association with the nuclear matrix. Journal of Cellular Biochemistry, 74(2), 152-167.
74. Sodek, J., Zhu, B., Huynh, M. H., Brown, T. J., & Ringuette, M. (2002). Novel functions of the matricellular proteins osteopontin and osteonectin/SPARC. Connective Tissue Research, 43(2-3), 308-319.
75. Yan, Q., Weaver, M., Perdue, N., & Sage, E. H. (2005). Matricellular protein SPARC is translocated to the nuclei of immortalized murine lens epithelial cells. Journal of Cellular Physiology, 203(1), 286-294.
76. Sage, E. H., Johnson, C., & Bornstein, P. (1984). Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. Journal of Biological Chemistry, 259, 3993-4007.
77. Funk, S. E., & Sage, E. H. (1993). Differential effects of SPARC and cationic SPARC peptides on DNA synthesis by endothelial cells and fibroblasts. Journal of Cellular Physiology, 154, 53-63.
78. 2+-binding glycoprotein SPARC modulates cell cycle progression in bovine aortic endothelial cells. Proceedings of the National Academy of the Sciences United States of America, 88, 2648-2652.
79. Kupprion, C., Motamed, K., & Sage, E. H. (1998). SPARC (BM-40, osteonectin) inhibits the mitogenic effect of vascular endothelial growth factor on microvascular endothelial cells. Journal of Biological Chemistry, 273(45), 29635-29640.
80. Lau, C. P., Poon, R. T., Cheung, S. T., Yu, W. C., & Fan, S. T. (2006). SPARC and hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. Journal of Pathology, 210(4), 459-468.
81. Charest, A., Pepin, A., Shetty, R., Cote, C., Voisine, P., Dagenais, F., et al. (2006). Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart, 92(12), 1844-1849.
82. Iruela Arispe, M. L., Lane, T. F., Redmond, D., Reilly, M., Bolender, R. P., Kavanagh, T. J., et al. (1995). Expression of SPARC during development of the chicken chorioallantoic membrane: Evidence for regulated proteolysis in vivo. Molecular Biology of the Cell, 6(3), 327-343.
83. Lane, T. F., Iruela-Arispe, M. L., Johnson, R. S., & Sage, E. H. (1994). SPARC is a source of copper-binding peptides that stimulate angiogenesis. Journal of Cell Biology, 125, 929-943.
84. Sage, E. H., Reed, M., Funk, S. E., Truong, T., Steadele, M., Puolakkainen, P., et al. (2003). Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis. Journal of Biological Chemistry, 278(39), 37849-37857.
85. Sasaki, T., Miosge, N., & Timpl, R. (1999). Immunochemical and tissue analysis of protease generated neoepitopes of BM-40 (osteonectin, SPARC) which are correlated to a higher affinity binding to collagens. Matrix Biology, 18(5), 499-508.
86. Kato, Y., Lewalle, J. M., Baba, Y., Tsukuda, M., Sakai, N., Baba, M., et al. (2001). Induction of SPARC by VEGF in human vascular endothelial cells. Biochemical and Biophysical Research Communications, 287(2), 422-426.
87. Nozaki, M., Sakurai, E., Raisler, B. J., Baffi, J. Z., Witta, J., Ogura, Y., et al. (2006). Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A. Journal of Clinical Investation, 116(2), 422-429.
88. Ferrari, G., Pintucci, G., Seghezzi, G., Hyman, K., Galloway, A. C., & Mignatti, P. (2006). VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proceedings of the National Academy of the Sciences United States of America, 103(46), 17260-17265.
89. Choi, M. E., & Ballermann, B. J. (1995). Inhibition of capillary morphogenesis and associated apoptosis by dominant negative mutant transforming growth factor-beta receptors. Journal of Biological Chemistry, 270(36), 21144-21150.
90. Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Review Cancer, 2(6), 442-454.
91. Cano, A., Perez-Moreno, M. A., Rodrigo, I., Locascio, A., Blanco, M. J., del Barrio, M. G., et al. (2000). The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nature Cell Biology, 2(2), 76-83.
92. De Craene, B., van Roy, F., & Berx, G. (2005). Unraveling signalling cascades for the Snail family of transcription factors. Cell Signal, 17(5), 535-547.
93. Moreno-Bueno, G., Cubillo, E., Sarrio, D., Peinado, H., Rodriguez-Pinilla, S. M., Villa, S., et al. (2006). Genetic profiling of epithelial cells expressing E-cadherin repressors reveals a distinct role for Snail, Slug, and E47 factors in epithelial-mesenchymal transition. Cancer Research, 66(19), 9543-9556.
94. Robert, G., Gaggioli, C., Bailet, O., Chavey, C., Abbe, P., Aberdam, E., et al. (2006). SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Research, 66(15), 7516-7523.
95. Alonso, S. R., Tracey, L., Ortiz, P., Perez-Gomez, B., Palacios, J., Pollan, M., et al. (2007). A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Research, 67(7), 3450-3460.
96. Bierie, B., & Moses, H. L. (2006). Tumour microenvironment: TGFbeta: The molecular Jekyll and Hyde of cancer. Nature Review Cancer, 6(7), 506-520.
97. Ford, R., Wang, G., Jannati, P., Adler, D., Racanelli, P., Higgins, P. J., et al. (1993). Modulation of SPARC expression during butyrate-induced terminal differentiation of cultured human keratinocytes: Regulation via a TGF-beta-dependent pathway. Experimental Cell Research, 206(2), 261-275.
98. Bassuk, J. A., Pichler, R., Rothmier, J. D., Pippen, J., Gordon, K., Meek, R. L., et al. (2000). Induction of TGF-beta1 by the matricellular protein SPARC in a rat model of glomerulonephritis. Kidney International, 57(1), 117-128.
99. Francki, A., Bradshaw, A. D., Bassuk, J. A., Howe, C. C., Couser, W. G., & Sage, E. H. (1999). SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. Journal of Biological Chemistry, 274(45), 32145-32152.
100. Reed, M. J., Vernon, R. B., Abrass, I. B., & Sage, E. H. (1994). TGF-b 1 induces the expression of type I collagen and SPARC, and enhances contraction of collagen gels, by fibroblasts from young and aged donors. Journal of Cellular Physiology, 158(1), 169-179.
101. Shiba, H., Uchida, Y., Kamihagi, K., Sakata, M., Fujita, T., Nakamura, S., et al. (2001). Transforming growth factor-beta1 and basic fibroblast growth factor modulate osteocalcin and osteonectin/SPARC syntheses in vitamin-D-activated pulp cells. Journal of Dental Research, 80(7), 1653-1659.
102. Wrana, J. L., Overall, C. M., & Sodek, J. (1991). Regulation of the expression of a secreted acidic protein rich in cysteine (SPARC) in human fibroblasts by transforming growth factor beta. comparison of transcriptional and post-transcriptional control with fibronectin and type I collagen. European Journal of Biochemistry, 197, 519-528.
103. Pavasant, P., Yongchaitrakul, T., Pattamapun, K., & Arksornnukit, M. (2003). The synergistic effect of TGF-beta and 1,25-dihydroxyvitamin D3 on SPARC synthesis and alkaline phosphatase activity in human pulp fibroblasts. Archives of Oral Biology, 48(10), 717-722.
104. Francki, A., McClure, T. D., Brekken, R. A., Motamed, K., Murri, C., Wang, T., et al. (2004). SPARC regulates TGF-beta1-dependent signaling in primary glomerular mesangial cells. Journal of Cellular Biochemistry, 91(5), 915-925.
105. Schiemann, B. J., Neil, J. R., & Schiemann, W. P. (2003). SPARC inhibits epithelial cell proliferation in part through stimulation of the TGF-beta-signaling system. Molecular Biology of the Cell, 14(10), 3977-3988.
106. Bradshaw, A. D., Reed, M. J., Carbon, J. G., Pinney, E., Brekken, R. A., & Sage, E. H. (2001). Increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges in SPARC-null mice. Wound Repair and Regeneration, 9(6), 522-530.
107. Peinado, H., Quintanilla, M., & Cano, A. (2003). Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: Mechanisms for epithelial mesenchymal transitions. Journal of Biological Chemistry, 278(23), 21113-21123.
108. McLean, G. W., Carragher, N. O., Avizienyte, E., Evans, J., Brunton, V. G., & Frame, M. C. (2005). The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nature Review Cancer, 5(7), 505-515.
109. Shi, Q., Bao, S., Song, L., Wu, Q., Bigner, D. D., Hjelmeland, A. B., et al. (2007). Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene, 26(28), 4084-4094.
110. Coussens, L. M., & Werb, Z. (1996). Matrix metalloproteinases and the development of cancer. Chemistry & Biology, 3, 895-904.
111. Alvarez, M. J., Prada, F., Salvatierra, E., Bravo, A. I., Lutzky, V. P., Carbone, C., et al. (2005). Secreted protein acidic and rich in cysteine produced by human melanoma cells modulates polymorphonuclear leukocyte recruitment and antitumor cytotoxic capacity. Cancer Research, 65(12), 5123-5132.
112. Savani, R. C., Zhou, Z., Arguiri, E., Wang, S., Vu, D., Howe, C. C., et al. (2000). Bleomycin-induced pulmonary injury in mice deficient in SPARC. AJP-Lung Physiol, 279(4), L743-750.
113. Sangaletti, S., Gioiosa, L., Guiducci, C., Rotta, G., Rescigno, M., Stoppacciaro, A., et al. (2005). Accelerated dendritic-cell migration and T-cell priming in SPARC-deficient mice. Journal of Cell Science, 118(Pt 16), 3685-3694.
114. Rempel, S. A., Hawley, R. C., Gutierrez, J. A., Mouzon, E., Bobbitt, K. R., Lemke, N., et al. (2007). Splenic and immune alterations of the Sparc-null mouse accompany a lack of immune response. Genes and Immunity, 8(3), 262-274.
115. Vannahme, C., Gosling, S., Paulsson, M., Maurer, P., & Hartmann, U. (2003). Characterization of SMOC-2, a modular extracellular calcium-binding protein. Biochemistry Journal, 373(Pt 3), 805-814.
116. Rocnik, E. F., Liu, P., Sato, K., Walsh, K., & Vaziri, C. (2006). The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity. Journal of Biological Chemistry, 281(32), 22855-22864.
117. Girard, J.-P., & Springer, T. A. (1995). Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity, 2, 113-123.
118. Girard, J.-P., & Springer, T. A. (1996). Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. Journal of Biological Chemistry, 271(8), 4511-4517.
119. Nelson, P. S., Plymate, S. R., Wang, K., True, L. D., Ware, J. L., Gan, L., et al. (1998). Hevin, an antiadhesive extracellular matrix protein, is down-regulated in metastatic prostate adenocarcinoma. Cancer Research, 58(2), 232-236.
120. Bendik, I., Schraml, P., & Ludwig, C. U. (1998). Characterization of MAST9/hevin, a SPARC-like protein, that is down-regulated in non-small cell lung cancer. Cancer Research, 58(4), 626-629.
121. Claeskens, A., Ongenae, N., Neefs, J. M., Cheyns, P., Kaijen, P., Cools, M., et al. (2000). Hevin is down-regulated in many cancers and is a negative regulator of cell growth and proliferation. British Journal of Cancer, 82(6), 1123-1130.
122. Esposito, I., Kayed, H., Keleg, S., Giese, T., Sage, E. H., Schirmacher, P., et al. (2007). Tumor-suppressor function of SPARC-like protein 1/hevin in pancreatic cancer. Neoplasia, 9(1), 8-17.
123. Jazaeri, A. A., Awtrey, C. S., Chandramouli, G. V., Chuang, Y. E., Khan, J., Sotiriou, C., et al. (2005). Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clinical Cancer Research, 11(17), 6300-6310.
124. Briggs, J., Chamboredon, S., Castellazzi, M., Kerry, J. A., & Bos, T. J. (2002). Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells. Oncogene, 21(46), 7077-7091.
125. Lopez, M. V., Blanco, P., Viale, D. L., Cafferata, E. G., Carbone, C., Gould, D., et al. (2006). Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growth. Molecular Cancer Therapeutics, 5(10), 2503-2511.
126. Zajchowski, D. A., Bartholdi, M. F., Gong, Y., Webster, L., Liu, H.-L., Munishkin, A., et al. (2001). Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Research, 61(13), 5168-5178.
127. Woelfle, U., Cloos, J., Sauter, G., Riethdorf, L., Janicke, F., van Diest, P., et al. (2003). Molecular signature associated with bone marrow micrometastasis in human breast cancer. Cancer Research, 63(18), 5679-5684.
128. Watkins, G., Martin, T. A., Bryce, R., Mansel, R. E., & Jiang, W. G. (2005). Gamma-linolenic acid regulates the expression and secretion of SPARC in human cancer cells. Prostaglandins Leukotrienes and Essential Fatty Acids, 72(4), 273-278.
129. Castronovo, V., & Bellahcene, A. (1998). Evidence that breast cancer associated microcalcifications are mineralized malignant cells. International Journal of Oncology, 12(2), 305-308.
130. Porter, D., Lahti-Domenici, J., Keshaviah, A., Bae, Y. K., Argani, P., Marks, J., et al. (2003). Molecular markers in ductal carcinoma in situ of the breast. Molecular Cancer Research, 1(5), 362-375.
131. Dairkee, S. H., Ji, Y., Ben, Y., Moore, D. H., Meng, Z., & Jeffrey, S. S. (2004). A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue. BMC Genomics, 5, 47.
132. Amatschek, S., Koenig, U., Auer, H., Steinlein, P., Pacher, M., Gruenfelder, A., et al. (2004). Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Research, 64(3), 844-856.
133. Jansen, M. P. H. M., Foekens, J. A., van Staveren, I. L., Dirkzwager-Kiel, M. M., Ritstier, K., Look, M. P., et al. (2005). Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. Journal of Clinical Oncology, 23(4), 732-740.
134. 3 integrin in human radial growth phase primary melanoma cells. Cancer Research, 62, 226-232.
135. Kuphal, S., Palm, H. G., Poser, I., & Bosserhoff, A. K. (2005). Snail-regulated genes in malignant melanoma. Melanoma Research, 15(4), 305-313.
136. Menon, P. M., Gutierrez, J. A., & Rempel, S. A. (2000). A study of SPARC and vitronectin localization and expression in pediatric and adult gliomas: High SPARC secretion correlates with decreased migration on vitronectin. International Journal of Oncology, 17(4), 683-693.
137. Huang, H., Colella, S., Kurrer, M., Yonekawa, Y., Kleihues, P., & Ohgaki, H. (2000). Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Research, 60(24), 6868-6874.
138. Rempel, S. A., Golembieski, W. A., Fisher, J. L., Maile, M., & Nakeff, A. (2001). SPARC modulates cell growth, attachment and migration of U87 glioma cells on brain extracellular matrix proteins. Journal of Neurooncology, 53, 149-160.
139. Golembieski, W. A., & Rempel, S. A. (2002). cDNA array analysis of SPARC-modulated changes in glioma gene expression. Journal of Neurooncology, 60(3), 213-226.
140. Zhou, X., Tan, F. K., Guo, X., Wallis, D., Milewicz, D. M., Xue, S., et al. (2005). Small interfering RNA inhibition of SPARC attenuates the profibrotic effect of transforming growth factor beta1 in cultured normal human fibroblasts. Arthritis and Rheumatism, 52(1), 257-261.
141. Cantarella, G., Risuglia, N., Dell'eva, R., Lempereur, L., Albini, A., Pennisi, G., et al. (2006). TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. British Journal of Cancer, 94(10), 1428-1435.
142. Kunigal, S., Gondi, C. S., Gujrati, M., Lakka, S. S., Dinh, D. H., Olivero, W. C., et al. (2006). SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. International Journal of Oncology, 29(6), 1349-1357.
143. Gagliano, N., Moscheni, C., Torri, C., Magnani, I., Bertelli, A. A., Nowicky, W., et al. (2006). Effect of Ukrain on matrix metalloproteinase-2 and secreted protein acidic and rich in cysteine (SPARC) expression in human glioblastoma cells. Anticancer Drugs, 17(2), 189-194.
144. Colin, C., Baeza, N., Bartoli, C., Fina, F., Eudes, N., Nanni, I., et al. (2006). Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using suppression subtractive hybridization. Oncogene, 25(19), 2818-2826.
145. Rempel, S. A., Ge, S., & Gutiérrez, J. A. (1999). SPARC: A potential diagnostic marker of invasive meningiomas. Clinical Cancer Research, 5, 237-241.
146. Rich, J. N., Hans, C., Jones, B., Iversen, E. S., McLendon, R. E., Rasheed, B. K., et al. (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Research, 65(10), 4051-4058.
147. Volmer, M. W., Radacz, Y., Hahn, S. A., Klein-Scory, S., Stuhler, K., Zapatka, M., et al. (2004). Tumor suppressor Smad4 mediates downregulation of the anti-adhesive invasion-promoting matricellular protein SPARC: Landscaping activity of Smad4 as revealed by a "secretome" analysis. Proteomics, 4(5), 1324-1334.
148. Sansom, O. J., Mansergh, F. C., Evans, M. J., Wilkins, J. A., & Clarke, A. R. (2007). Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice. Gut, 56(10), 1410-1414.
149. Madoz-Gurpide, J., Lopez-Serra, P., Martinez-Torrecuadrada, J. L., Sanchez, L., Lombardia, L., & Casal, J. I. (2006). Proteomics-based validation of genomic data: Applications in colorectal cancer diagnosis. Molecular and Cellular Proteomics, 5(8), 1471-1483.
150. Kaiser, S., Park, Y. K., Franklin, J. L., Halberg, R. B., Yu, M., Jessen, W. J., et al. (2007). Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biology, 8, R131.
151. Lecrone, V., Li, W., Devoll, R. E., Logothetis, C., & Farach-Carson, M. C. (2000). Calcium signals in prostate cancer cells: Specific activation by bone-matrix proteins. Cell Calcium, 27(1), 35-42.
152. Thomas, R., True, L. D., Bassuk, J. A., Lange, P. H., & Vessella, R. L. (2000). Differential expression of osteonectin/SPARC during human prostate cancer progression. Clinical Cancer Research, 6(3), 1140-1149.
153. Lapointe, J., Li, C., Higgins, J. P., van de Rijn, M., Bair, E., Montgomery, K., et al. (2004). Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proceedings of the National Academy of the Sciences United States of America, 101(3), 811-816.
154. Best, C. J., Gillespie, J. W., Yi, Y., Chandramouli, G. V., Perlmutter, M. A., Gathright, Y., et al. (2005). Molecular alterations in primary prostate cancer after androgen ablation therapy. Clinical Cancer Research, 11(19 Pt 1), 6823-6834.
155. Kato, Y., Sakai, N., Baba, M., Kaneko, S., Kondo, K., Kubota, Y., et al. (1998). Stimulation of motility of human renal cell carcinoma by SPARC/Osteonectin/BM-40 associated with type IV collagen. Invasion Metastasis, 18(2), 105-114.
156. Sakai, N., Baba, M., Nagasima, Y., Kato, Y., Hirai, K., Kondo, K., et al. (2001). SPARC expression in primary human renal cell carcinoma: Upregulation of SPARC in sarcomatoid renal carcinoma. Human Pathology, 32(10), 1064-1070.
157. Gieseg, M. A., Cody, T., Man, M. Z., Madore, S. J., Rubin, M. A., & Kaldjian, E. P. (2002). Expression profiling of human renal carcinomas with functional taxonomic analysis. BMC Bioinformatics, 3, 26.
158. 2+-relevant and differentiation-associated genes downregulated in esophageal squamous cell carcinoma using cDNA microarray. Oncogene, 23(6), 1291-1299.
159. Mitas, M., Almeida, J. S., Mikhitarian, K., Gillanders, W. E., Lewin, D. N., Spyropoulos, D. D., et al. (2005). Accurate discrimination of Barrett's esophagus and esophageal adenocarcinoma using a quantitative three-tiered algorithm and multimarker real-time reverse transcription-PCR. Clinical Cancer Research, 11(6), 2205-2214.
160. Che, Y., Luo, A., Wang, H., Qi, J., Guo, J., & Liu, Z. (2006). The differential expression of SPARC in esophageal squamous cell carcinoma. International Journal of Molecular Medicine, 17(6), 1027-1033.
161. Porte, H., Triboulet, J. P., Kotelevets, L., Carrat, F., Prevot, S., Nordlinger, B., et al. (1998). Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: Implications for prognosis. Clininal Cancer Research, 4(6), 1375-1382.
162. Yamashita, K., Upadhay, S., Mimori, K., Inoue, H., & Mori, M. (2003). Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer, 97(10), 2412-2419.
163. Brabender, J., Marjoram, P., Lord, R. V., Metzger, R., Salonga, D., Vallbohmer, D., et al. (2005). The molecular signature of normal squamous esophageal epithelium identifies the presence of a field effect and can discriminate between patients with Barrett's esophagus and patients with Barrett's-associated adenocarcinoma. Cancer Epidemiology, Biomarkers & Prevention, 14(9), 2113-2117.
164. Siddiq, F., Sarkar, F. H., Wali, A., Pass, H. I., & Lonardo, F. (2004). Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. Lung Cancer, 45(2), 197-205.
165. De Vos, J., Thykjaer, T., Tarte, K., Ensslen, M., Raynaud, P., Requirand, G., et al. (2002). Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene, 21(44), 6848-6857.
166. Hedvat, C. V., Comenzo, R. L., Teruya-Feldstein, J., Olshen, A. B., Ely, S. A., Osman, K., et al. (2003). Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. British Journal of Haematology, 122(5), 728-744.
167. Martinez, N., Camacho, F. I., Algara, P., Rodriguez, A., Dopazo, A., Ruiz-Ballesteros, E., et al. (2003). The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. Cancer Research, 63(23), 8226-8232.
168. Aouacheria, A., Navratil, V., Lopez-Perez, R., Gutierrez, N. C., Churkin, A., Barash, D., et al. (2007). In silico whole-genome screening for cancer-related single-nucleotide polymorphisms located in human mRNA untranslated regions. BMC Genomics, 8, 2.
169. Bloomston, M., Ellison, E. C., Muscarella, P., Al-Saif, O., Martin, E. W., Melvin, W. S., et al. (2007). Stromal osteonectin overexpression is associated with poor outcome in patients with ampullary cancer. Annalsof Surgical Oncology, 14(1), 211-217.
170. Prenzel, K. L., Warnecke-Eberz, U., Xi, H., Brabender, J., Baldus, S. E., Bollschweiler, E., et al. (2006). Significant overexpression of SPARC/osteonectin mRNA in pancreatic cancer compared to cancer of the papilla of Vater. Oncology Reports, 15(5), 1397-1401.
171. Le Bail, B., Faouzi, S., Boussarie, L., Guirouilh, J., Blanc, J. F., Carles, J., et al. (1999). Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. Journal of Pathology, 189(1), 46-52.
172. Goldenberg, D., Ayesh, S., Schneider, T., Pappo, O., Jurim, O., Eid, A., et al. (2002). Analysis of differentially expressed genes in hepatocellular carcinoma using cDNA arrays. Molecular Carcinogenesis, 33, 113-124.
173. Maeng, H. Y., Song, S. B., Choi, D. K., Kim, K. E., Jeong, H. Y., Sakaki, Y., et al. (2002). Osteonectin-expressing cells in human stomach cancer and their possible clinical significance. Cancer Letters, 184(1), 117-121.
174. Inoue, H., Matsuyama, A., Mimori, K., Ueo, H., & Mori, M. (2002). Prognostic score of gastric cancer determined by cDNA microarray. Clinical Cancer Research, 8(11), 3475-3479.
175. Wang, C. S., Lin, K. H., Chen, S. L., Chan, Y. F., & Hsueh, S. (2004). Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. British Journal of Cancer, 91(11), 1924-1930.
176. Paley, P. J., Goff, B. A., Gown, A. M., Greer, B. E., & Sage, E. H. (2000). Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecologic Oncology, 78(3 Pt 1), 336-341.
177. Nimphius, W., Moll, R., Olbert, P., Ramaswamy, A., & Barth, P. J. (2007). CD34+ fibrocytes in chronic cystitis and noninvasive and invasive urothelial carcinomas of the urinary bladder. Virchows Archiv, 450(2), 179-185.
178. Yamanaka, M., Kanda, K., Li, N.-C., Fukumori, T., Oka, N., Kanayama, H.-O., et al. (2001). Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. Journal of Urology, 166, 2495-2499.
179. Chen, Y., Miller, C., Mosher, R., Zhao, X., Deeds, J., Morrissey, M., et al. (2003). Identification of cervical cancer markers by cDNA and tissue microarrays. Cancer Research, 63(8), 1927-1935.
180. Sova, P., Feng, Q., Geiss, G., Wood, T., Strauss, R., Rudolf, V., et al. (2006). Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiology, Biomarkers & Prevention, 15(1), 114-123.
181. Rodriguez-Jimenez, F. J., Caldes, T., Iniesta, P., Vidart, J. A., Garcia-Asenjo, J. L., & Benito, M. (2007). Overexpression of SPARC protein contrasts with its transcriptional silencing by aberrant hypermethylation of SPARC CpG-rich region in endometrial carcinoma. Oncology Reports, 17(6), 1301-1307.
182. Fanburg-Smith, J. C., Bratthauer, G. L., & Miettinen, M. (1999). Osteocalcin and osteonectin immunoreactivity in extraskeletal osteosarcoma: A study of 28 cases. Human Pathology, 30(1), 32-38.
183. Dalla-Torre, C. A., Yoshimoto, M., Lee, C. H., Joshua, A. M., de Toledo, S. R., Petrilli, A. S., et al. (2006). Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma. BMC Cancer, 6(1), 237.
184. Takano, T., Hasegawa, Y., Miyauchi, A., Matsuzuka, F., Yoshida, H., Kuma, K., et al. (2002). Quantitative analysis of osteonectin mRNA in thyroid carcinomas. Endocrine Journal, 49(4), 511-516.
185. Chin, D., Boyle, G. M., Williams, R. M., Ferguson, K., Pandeya, N., Pedley, J., et al. (2005). Novel markers for poor prognosis in head and neck cancer. International Journal of Cancer, 113(5), 789-797.
186. Aycock, R. L., Bradshaw, A. C., Sage, E. H., & Starcher, B. (2004). Development of UV-induced squamous cell carcinomas is suppressed in the absence of SPARC. Journal of Investigative Dermatology, 123(3), 592-599.
187. Said, N., Najwer, I., & Motamed, K. (2007). Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. American Journal of Pathology, 170(3), 1054-1063.
188. Cody, N. A., Ouellet, V., Manderson, E. N., Quinn, M. C., Filali-Mouhim, A., Tellis, P., et al. (2007). Transfer of chromosome 3 fragments suppresses tumorigenicity of an ovarian cancer cell line monoallelic for chromosome 3p. Oncogene, 26(4), 618-632.
189. Dhanesuan, N., Sharp, J. A., Blick, T., Price, J. T., & Thompson, E. W. (2002). Doxycycline-inducible expression of SPARC/Osteonectin/BM40 in MDA-MB-231 human breast cancer cells results in growth inhibition. Breast Cancer Research and Treatment, 75(1), 73-85.
190. Bergamaschi, A., Tagliabue, E., Sorlie, T., Naume, B., Triulzi, T., Orlandi, R., et al. (2007). Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Journal of Pathology, 214(3), 357-367.
191. Tang, H., Wang, J., Bai, F., Hong, L., Liang, J., Gao, J., et al. (2007). Inhibition of osteopontin would suppress angiogenesis in gastric cancer. Biochemistry and Cell Biology, 85(1), 103-110.
192. Chlenski, A., Liu, S., Guerrero, L. J., Yang, Q., Tian, Y., Salwen, H. R., et al. (2006). SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. International Journal of Cancer, 118(2), 310-316.
193. Chlenski, A., Guerrero, L. J., Yang, Q., Tian, Y., Peddinti, R., Salwen, H. R., et al. (2007). SPARC enhances tumor stroma formation and prevents fibroblast activation. Oncogene, 26(31), 4513-4522.
194. Puolakkainen, P., Bradshaw, A. D., Kyriakides, T. R., Reed, M., Brekken, R., Wight, T., et al. (2003). Compromised production of extracellular matrix in mice lacking secreted protein, acidic and rich in cysteine (SPARC) leads to a reduced foreign body reaction to implanted biomaterials. American Journal of Pathology, 162(2), 627-635.
195. DiMartino, J. F., Lacayo, N. J., Varadi, M., Li, L., Saraiya, C., Ravindranath, Y., et al. (2006). Low or absent SPARC expression in acute myeloid leukemia with MLL rearrangements is associated with sensitivity to growth inhibition by exogenous SPARC protein. Leukemia, 20(3), 426-432.